Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifestyle intervention and metformin for prevention of progression from prediabetes to type 2 diabetes
IRCT20241016063389N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of metformin and Placebo-COD Research Private Ltd in prediabetes (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Weight loss of at least 7% of initial body weight. Started Nov 2024; status: completed.
02
Drugs
metforminPlacebo-COD Research Private Ltd
03
Conditions
prediabetes
Beyond the preview
Go deeper on IRCT20241016063389N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241016063389N1.